KLOW Stack Protocol - BPC-157 + TB-500 + GHK-Cu + KPV

Quick Reference Dosing Card

What Is the KLOW Stack?

The KLOW Stack protocol combines four peptides, BPC-157, TB-500, GHK-Cu, and KPV, to target tissue repair, skin and collagen quality, and inflammation control in a single regimen. Each compound works through a different biological pathway: BPC-157 supports blood vessel formation, TB-500 helps repair cells reach injured tissue, GHK-Cu promotes collagen remodeling and skin quality, and KPV directly reduces inflammation.

KLOW builds on the three-peptide GLOW Stack (BPC-157 + TB-500 + GHK-Cu) by adding KPV, a short peptide fragment that blocks a key inflammation switch called NF-kB. This makes KLOW a common choice when chronic inflammation is limiting the body's response to repair-focused stacks alone. It is also popular for gut-barrier support, since both KPV and BPC-157 can be taken orally.

No direct clinical trial has evaluated the full four-peptide combination; protocols are extrapolated from individual evidence and practitioner/community usage patterns.

Why Add KPV to the GLOW Stack?

Foundation: GLOW (BPC-157 + TB-500 + GHK-Cu)

The GLOW Stack already provides three layers of support — tissue repair (BPC-157), cell migration to injury sites (TB-500), and collagen remodeling (GHK-Cu). KLOW keeps all three and adds a fourth layer: dedicated inflammation control through KPV.

Pathway 1: Inflammation Control — Clearing the Way for Repair

When inflammation stays elevated, the body's repair processes slow down. KPV targets a central inflammation switch (NF-kB) and helps lower the inflammatory "noise," which may create a better environment for the repair and remodeling work of the other three peptides. Think of it like clearing debris from a construction site so the builders can work more efficiently.

Pathway 2: Gut-Focused Oral Synergy — Fewer Injections for Gut Support

Both KPV and BPC-157 can be taken orally in many protocols. This means you can build a gut-focused version of the KLOW Stack that uses only two daily injections (TB-500 and GHK-Cu) while the other two compounds are swallowed as oral doses — especially useful if gut-barrier repair or digestive inflammation is your primary goal.

Pathway 3: Antimicrobial Coverage — An Extra Layer the Others Don't Provide

KPV has antimicrobial properties that the other three compounds lack. In scenarios where inflammation is accompanied by microbial imbalance (such as certain gut conditions), this adds coverage that a repair-only stack cannot provide.

Pathway 4: Combined Anti-Inflammatory Strength

All four peptides reduce inflammation through different biological routes. When stacked together, KLOW delivers the strongest anti-inflammatory coverage of any standard stack variant — each compound contributes a different piece of the inflammation-control puzzle.

KLOW Stack Dosing Protocol & Schedule

This section covers three ways to run the KLOW Stack dosing protocol: separate vials (most flexible), a pre-blended vial (most convenient), and an oral-hybrid option for gut-focused use. Choose the format that fits your workflow, then use the tables below to match dosing, injection count, and reconstitution setup.

In the dosing tables below, SubQ means a subcutaneous injection placed just under the skin into the fat layer.

• Separate-vial protocols preserve full dose control and oral-hybrid flexibility.
• Pre-blended protocols reduce daily injection burden to one injection but lock ratios.
• KPV and BPC-157 can remain oral in separate-vial/hybrid models while TB-500 and GHK-Cu stay injectable.

KLOW Stack Reconstitution Guide

• BPC-157 and KPV are typically dosed in micrograms (mcg) — these are very small amounts.
• TB-500 and GHK-Cu are typically dosed in milligrams (mg) — 1,000 times larger than a microgram.
• Confusing mcg and mg could result in a dose that is 1,000x too high or too low. Label every vial clearly with its name, concentration, and unit.

Standard 7-Step Reconstitution

1. Wipe stopper and let dry.
2. Draw BAC water with sterile syringe.
3. Direct water against glass wall.
4. Roll gently; do not shake.
5. Inspect expected clarity/color.
6. Label with name, concentration, date.
7. Refrigerate and use within stability window.

KLOW Stack Side Effects & Safety

Each of the four KLOW Stack compounds has a favorable safety profile in the research that exists for it individually. However, no clinical trial has tested all four together, so combined effects are theoretical.

• Combined blood-vessel stimulation: Three of the four compounds (BPC-157, TB-500, and GHK-Cu) promote new blood vessel growth. In theory, stacking all three amplifies this effect, which is a concern for anyone with a history of cancer or active tumors — new blood vessels can feed tumor growth. If you have a cancer history, discuss this with a clinician before considering any angiogenic (blood-vessel-promoting) peptide stack.
• Copper cycling with GHK-Cu: GHK-Cu delivers copper into the body. Prolonged use without breaks can lead to copper accumulation, so most protocols include 30–60 day on-cycles followed by equal off-periods. This compound is contraindicated for people with Wilson's disease or other copper metabolism disorders.
• Deeper inflammation suppression: KPV and GHK-Cu both reduce inflammation through the same central inflammation-switch pathway described above. Together, they may suppress inflammation more aggressively than either alone — which is the goal for most users, but worth monitoring in case of over-suppression.
• Quality control risk: Using four separate compounds from potentially four different suppliers increases contamination risk. Source all compounds from COA-verified suppliers to reduce this concern.

Common community-reported effects include mild injection-site irritation, temporary fatigue during the first 1–2 weeks of TB-500 loading, and mild GI effects (nausea, loose stool) when oral KPV is dosed at the higher end of the range.

Clinical Evidence Context

The KLOW Stack is designed to address each of the four main barriers to tissue repair: blood supply, cell migration to the injury, collagen and tissue quality, and inflammation control. Each compound targets a different barrier.

Storage & Handling

TB-500 remains the limiting stability factor in separate-vial storage planning.

KLOW vs GLOW vs Wolverine

Choose KLOW when inflammatory burden is central to the case profile. Choose GLOW when skin/remodeling is priority without high inflammatory complexity. Choose Wolverine when simplicity and repair-first coverage are sufficient.

Related Stacking Protocols

GLOW Stack (BPC-157 + TB-500 + GHK-Cu)

Three-peptide predecessor model emphasizing repair plus collagen/skin remodeling. View GLOW Stack.

Wolverine Stack (BPC-157 + TB-500)

Foundational two-peptide repair model for lower complexity workflows. View Wolverine Stack.

KLOW + GH Secretagogue

Adding CJC-1295/Ipamorelin is sometimes used for recovery-phase GH pulse support during intensive regenerative cycles.

Frequently Asked Questions - KLOW Stack

Sources & Research

1. Dalmasso G, et al. "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." Gastroenterology, 2008 Link.
2. Vasireddi N, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." Orthopaedic Journal of Sports Medicine, 2025.
3. Ruff D, et al. "A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers." Annals of the New York Academy of Sciences, 2010.
4. Pickart L, Margolina A "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018 Link.
5. Xiao B, et al. "Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis." Molecular Therapy, 2017 Link.
6. Bock-Marquette I, et al. "Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature, 2004.
7. Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature, 2007.
8. Brzoska T, et al. "α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Annals of the Rheumatic Diseases, 2008 Link.
9. Sikiric P, et al. "The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity." Pharmaceuticals, 2024.
10. Catania A, et al. "Antimicrobial properties of alpha-MSH and related synthetic melanocortins." Journal of Leukocyte Biology, 2000.
11. Yuvan Research / McGill University "Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial." EurekAlert, 2024.
12. Broad Institute Connectivity Map "Gene expression analysis of GHK-Cu." CLUE, 2024 Link.

Related Protocols

Disclaimer